Epoxylipids and soluble epoxide hydrolase in heart diseases

This publication has 101 references indexed in Scilit:

• Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease
  Atherosclerosis, 2012
• Inhibition of soluble epoxide hydrolase bycis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension
  Clinical Science, 2012
• Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury
  British Journal of Pharmacology, 2011
• Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension‐induced renal injury in mice
  The FASEB Journal, 2010
• Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling
  American Journal of Physiology-Heart and Circulatory Physiology, 2010
• Inhibition of Soluble Epoxide Hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid Is Protective Against Ischemia–Reperfusion Injury
  Journal of Cardiovascular Pharmacology, 2010
• Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches
  Journal of Molecular and Cellular Cardiology, 2009
• Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
  Nature Reviews Drug Discovery, 2009
• Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury
  Prostaglandins & Other Lipid Mediators, 2007
• Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors
  Proceedings of the National Academy of Sciences, 2006